T-817MA is under clinical development by FUJIFILM Toyama Chemical and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how T-817MA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
T-817MA overview
T-817MA is under development for the treatment of Alzheimer's disease, mild cognitive impairment due to Alzheimer’s disease and rehabilitation effects after stroke, unilateral upper limb paralysis (Hemiplegia) following cerebral infarction or cerebral hemorrhage. The drug candidate is administered by oral route. T-817MA is a neurotrophic agent and a maleate salt of T-817. T-817MA targets amyloid beta protein (amyloid precursor protein).
FUJIFILM Toyama Chemical overview
FUJIFILM Toyama Chemical, a subsidiary of Fujifilm Holdings Corp, develops and manufactures new diagnostic and therapeutic drugs for the treatment of oncology indications, central nervous system disorders and infectious diseases. The company offers products which include radiopharmaceuticals used for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging; radioiodine for thyroid therapy; non-ionic X-ray contrast medium; and pharmaceuticals for diagnostic imaging. It develops pipeline products for the treatment of respiratory and otorhinolaryngology infectious diseases, Alzheimer’s disease, prostate cancer, pheochromocytoma tumour and influenza virus. The company operates manufacturing factories in Toyama and Chiba regions. FUJIFILM Toyama Chemical is headquartered in Tokyo, Japan.
For a complete picture of T-817MA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
